HUB LOGIN
PATIENTS

PCOS Is Now PMOS – Why The Name Change Matters

May 2026

A major shift has officially arrived in women’s health. The condition long known as polycystic ovary syndrome (PCOS) has been renamed polyendocrine metabolic ovarian syndrome (PMOS) following an extensive international consensus process published in The Lancet in May 2026.

This change is much more than semantics. It reflects decades of growing evidence that the condition extends far beyond the ovaries and is fundamentally a complex endocrine and metabolic disorder with systemic health implications. For many clinicians and patients, the new terminology finally aligns the name of the condition with what research has shown all along. 

Why the Name “PCOS” Was Problematic 

The term polycystic ovary syndrome has historically created confusion for both patients and providers. Despite the name, people with PCOS do not actually develop pathological ovarian cysts. Instead, the ovaries often contain numerous immature follicles that are never allowed to mature due to disrupted ovulation and endocrine signaling, that lead to the “string of pearls” sign often seen on ovarian ultrasound. And as we know, not all women with PCOS even have this presentation, making the name misleading. 

The review article highlights several major concerns with the old terminology: 

  • It overly emphasized the ovaries while minimizing the systemic nature of the condition
  • It reinforced the misconception that ovarian cysts are central to diagnosis
  • It contributed to delayed diagnosis and fragmented care
  • It obscured the significant metabolic and endocrine dysfunction involved
  • It created stigma surrounding fertility and reproduction
  • It limited research framing and policy development

Up to 70% of affected individuals remain undiagnosed, in part because the name itself fails to reflect the broad clinical presentation

What Does PMOS Mean?

The new term — polyendocrine metabolic ovarian syndrome — was selected after a global consensus process involving: 

  • More than 14,000 survey responses
  • Patients from multiple world regions
  • Multidisciplinary healthcare professionals
  • International endocrine, reproductive, metabolic, and patient advocacy organizations
Each component of the new name was chosen intentionally:
Polyendocrine

This reflects the reality that PMOS is not simply an ovarian condition. Multiple endocrine systems are involved, including: 

  • Insulin signaling 
  • Androgen production 
  • Neuroendocrine pathways 
  • Ovarian hormone regulation 
  • Adrenal influences 
  • Appetite and metabolic signaling

The article emphasizes that PMOS has polygenic origins affecting neuroendocrine, metabolic, and reproductive pathways simultaneously.

Metabolic 

This was considered essential because insulin resistance and metabolic dysfunction are foundational features of the condition. 

Research cited in the review notes: 

  • Approximately 85% of individuals with PMOS demonstrate insulin resistance 
  • Cardiometabolic risks are significantly elevated 
  • Risks include dysglycemia, type 2 diabetes, hypertension, dyslipidemia, MASLD (previously NAFLD), and cardiovascular disease
Ovarian 

The ovarian component remains important because ovarian dysfunction is central to diagnosis and symptom expression. PMOS commonly involves: 

  • Ovulatory dysfunction 
  • Altered folliculogenesis 
  • Hyperandrogenism 
  • Elevated AMH 
  • Menstrual irregularity 
  • Infertility

However, the new name removes the misleading implication of “cysts” while still acknowledging ovarian involvement.

Multisystem Framing

A Shift Toward Whole-Body Understanding 

One of the most important implications of this transition is that PMOS reframes the condition as a multisystem disorder rather than solely a reproductive syndrome. 

The review emphasizes that PMOS impacts: 

  • Metabolic health 
  • Cardiovascular risk 
  • Liver health 
  • Mental health 
  • Dermatologic health 
  • Fertility and pregnancy outcomes 
  • Sleep 
  • Long-term chronic disease risk 

This broader framing may help clinicians move beyond a narrow fertility-centered model and encourage more comprehensive screening and care. 

Endocrine and metabolic dysfunction affect health across the entire lifespan — including after reproductive years. 

For years, many patients with PCOS symptoms were told they only needed treatment if they wanted to become pregnant. The PMOS framework acknowledges that endocrine and metabolic dysfunction affect health across the entire lifespan — including after reproductive years. 

Why This Matters Clinically 

The name change may seem subtle, but it has important implications for both patient care and clinical education. 

1. Improved Diagnostic Awareness 

The new terminology may help providers recognize presentations that extend beyond irregular cycles or ovarian ultrasound findings. Patients often present with:

  • Insulin resistance
  • Fatigue
  • Mood changes 
  • Acne or hirsutism 
  • Weight dysregulation 
  • Dysglycemia
  • Inflammation 
  • Sleep disturbances
2. Reduced Stigma 

The consensus process placed strong emphasis on stigma reduction.

Many patients reported distress surrounding the reproductive focus of the old name, particularly in cultures where fertility strongly influences social identity.

The removal of “polycystic” may also reduce fear and misunderstanding around ovarian cysts. The PMOS framework better supports investigation into interconnected systems. 

3. Expanded Research and Policy Alignment 

The authors note that more accurate terminology can improve: 

  • Research consistency 
  • Funding prioritization 
  • Disease classification 
  • ICD coding 
  • Public health policy alignment

This may ultimately accelerate advancements in metabolic, endocrine, and reproductive treatment approaches. 

What Happens Next? 

The transition from PCOS to PMOS will occur gradually over approximately three years. The implementation strategy includes: 

  • Updates to clinical guidelines 
  • Integration into electronic medical records 
  • ICD coding revisions 
  • Educational campaigns 
  • International policy adoption 
  • Updated textbooks and provider resources 

The 2028 International Guidelines are expected to formally incorporate the PMOS terminology globally. 

A Step Toward More Comprehensive Care 

Although the research is finally catching up to what functional and integrative medicine has recognized for years—that PMOS is systemic, multifactorial, and deeply interconnected—the transition from PCOS to PMOS represents an important step toward more comprehensive and personalized care. 

The updated framework reinforces that this condition is not simply about ovarian cysts or irregular cycles. Rather, it involves complex interactions between insulin signaling, androgen synthesis, inflammation, metabolic health, follicular development, neuroendocrine communication, and long-term cardiometabolic risk.

As the understanding of PMOS continues to evolve, treatment approaches will likely continue shifting away from isolated symptom management and toward comprehensive metabolic, endocrine, and ovarian support. 

Connect with a functional medicine practitioner near you – use our Find a Practitioner tool today!
Click here

  1. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00717-8/fulltext 

Share:

Facebook
Twitter
Pinterest
LinkedIn

Related Posts

Establishing Our Inner Connection

Swadhyaya, from the Sanskrit sva (self) and adhyaya (study), refers to the disciplined practice of self-inquiry. Rooted in Indian spiritual traditions, it involves reflection, scriptural

Tagged